Sanofi CEO Olivier Brandicourt testifies before the US Senate finance committee in Washington DC, on February 26 2019. Picture: GETTY IMAGES/WIN MCNAMEE
. At the same time, research chief John Reed is hunting for opportunities in cancer after Sanofi missed out on the recent wave of revolutionary medicines focused on the immune system. Two acquisitions have delivered new experimental therapies for bleeding disorders. First-quarter earnings excluding some items rose 11% to €1.42 a share in the first quarter, the French drug maker said in a statement. Analysts predicted €1.32. The company maintained its forecast for 2019.The results highlight the significance of vaccines in partly sheltering the company from the pricing pressure its drugs face in the US. Vaccines sales surged 20%.